9 assets in Astrocytoma, IDH-Mutant, Grade 2

Therapeutic assets addressing Astrocytoma, IDH-Mutant, Grade 2, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Safusidenib Astrocytoma, IDH-Mutant, Grade 2	Nuvation Bio Inc.	P3	B (60)
Carboplatin Astrocytoma, IDH-Mutant, Grade 2	Neonc Technologies, Inc.	P1/2	CC (45)
Ipilimumab Astrocytoma, IDH-Mutant, Grade 2	Neonc Technologies, Inc.	P1/2	CC (45)
neo212 Astrocytoma, IDH-Mutant, Grade 2	Neonc Technologies, Inc.	P1/2	CC (45)
Nivolumab Astrocytoma, IDH-Mutant, Grade 2	Neonc Technologies, Inc.	P1/2	CC (45)
Pembrolizumab Astrocytoma, IDH-Mutant, Grade 2	Neonc Technologies, Inc.	P1/2	CC (45)
Regorafenib Astrocytoma, IDH-Mutant, Grade 2	Neonc Technologies, Inc.	P1/2	CC (45)
Telaglenastat Astrocytoma, IDH-Mutant, Grade 2	National Cancer Institute (NCI)	P1	CC (43)
Triapine Astrocytoma, IDH-Mutant, Grade 2	National Cancer Institute (NCI)	P1	CC (43)